AU2015311637B2 - Methods and biocompatible compositions to achieve sustained drug release in the eye - Google Patents

Methods and biocompatible compositions to achieve sustained drug release in the eye Download PDF

Info

Publication number
AU2015311637B2
AU2015311637B2 AU2015311637A AU2015311637A AU2015311637B2 AU 2015311637 B2 AU2015311637 B2 AU 2015311637B2 AU 2015311637 A AU2015311637 A AU 2015311637A AU 2015311637 A AU2015311637 A AU 2015311637A AU 2015311637 B2 AU2015311637 B2 AU 2015311637B2
Authority
AU
Australia
Prior art keywords
drug
wafer
nanostructured biocompatible
nanomesh
nanostructured
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015311637A
Other languages
English (en)
Other versions
AU2015311637A1 (en
Inventor
Koushik BARMAN
Shikha P. Barman
Brendan Hackett
Moli LIU
Kevin L. Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Integral Biosystems LLC
Original Assignee
Integral Biosystems LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Integral Biosystems LLC filed Critical Integral Biosystems LLC
Publication of AU2015311637A1 publication Critical patent/AU2015311637A1/en
Application granted granted Critical
Publication of AU2015311637B2 publication Critical patent/AU2015311637B2/en
Priority to AU2019250153A priority Critical patent/AU2019250153B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
AU2015311637A 2014-09-06 2015-09-08 Methods and biocompatible compositions to achieve sustained drug release in the eye Active AU2015311637B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2019250153A AU2019250153B2 (en) 2014-09-06 2019-10-16 Methods and biocompatible compositions to achieve sustained drug release in the eye

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462046918P 2014-09-06 2014-09-06
US62/046,918 2014-09-06
PCT/US2015/048795 WO2016037169A1 (en) 2014-09-06 2015-09-08 Methods and biocompatible compositions to achieve sustained drug release in the eye

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019250153A Division AU2019250153B2 (en) 2014-09-06 2019-10-16 Methods and biocompatible compositions to achieve sustained drug release in the eye

Publications (2)

Publication Number Publication Date
AU2015311637A1 AU2015311637A1 (en) 2017-03-23
AU2015311637B2 true AU2015311637B2 (en) 2019-07-18

Family

ID=55440434

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015311637A Active AU2015311637B2 (en) 2014-09-06 2015-09-08 Methods and biocompatible compositions to achieve sustained drug release in the eye
AU2019250153A Active AU2019250153B2 (en) 2014-09-06 2019-10-16 Methods and biocompatible compositions to achieve sustained drug release in the eye

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2019250153A Active AU2019250153B2 (en) 2014-09-06 2019-10-16 Methods and biocompatible compositions to achieve sustained drug release in the eye

Country Status (12)

Country Link
US (2) US9931306B2 (enExample)
EP (1) EP3188688B1 (enExample)
JP (2) JP7026507B2 (enExample)
KR (1) KR102456032B1 (enExample)
CN (2) CN109481447A (enExample)
AU (2) AU2015311637B2 (enExample)
CA (1) CA2960213C (enExample)
ES (1) ES2900025T3 (enExample)
MY (1) MY178327A (enExample)
SG (1) SG11201701714RA (enExample)
WO (1) WO2016037169A1 (enExample)
ZA (2) ZA201701467B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2900025T3 (es) * 2014-09-06 2022-03-15 Integral Biosystems Llc Procedimientos y composiciones biocompatibles para lograr la liberación mantenida de fármaco en el ojo
US11458041B2 (en) * 2015-10-08 2022-10-04 Ocular Therapeutix, Inc. Punctal plug and bioadhesives
EP4046609B1 (en) * 2016-09-30 2025-02-26 Mati Therapeutics Inc. Ophthalmic drug sustained release formulation and uses thereof
WO2018217662A1 (en) * 2017-05-22 2018-11-29 California Institute Of Technology Small molecule transport device with anti-condensation filler for drug delivery or waste removal
US20200206137A1 (en) * 2017-07-17 2020-07-02 Wolfcreek Biotech Pte Ltd Microparticle formulations for delivery of active agents
IL276899B2 (en) * 2018-03-01 2025-09-01 Univ Bar Ilan System, method and composition of materials for use in the treatment of visual disorders
WO2019234741A1 (en) * 2018-06-05 2019-12-12 Corneat Vision Ltd. A synthetic ophthalmic graft patch
CN109853054A (zh) * 2019-02-27 2019-06-07 上海交通大学医学院附属第九人民医院 一种同轴静电纺丝三维打印生物支架的装置及搭建方法
EP3701974B1 (en) * 2019-02-28 2024-08-28 Agency for Science, Technology and Research A material suitable for use as a vitreous substitute and related methods
JP7570342B2 (ja) 2019-03-05 2024-10-21 アエリエ ファーマシューティカルズ インコーポレイテッド 眼の疾患又は障害を治療するための医薬組成物
CN114126658A (zh) * 2019-04-02 2022-03-01 细胞质基质有限公司 用于递送生物活性剂的组合物及其用途
TWI826685B (zh) 2019-05-02 2023-12-21 瑞士商愛爾康公司 可溶解聚合物眼睛插入物及其使用方法
JP2022553408A (ja) 2019-10-24 2022-12-22 デニス・イー・ラボンバード 眼用デバイスおよび薬物送達システムならびにそのケース
KR20220084381A (ko) * 2019-12-10 2022-06-21 알콘 인코포레이티드 생분해성 중합체를 갖는 용해성 중합체 눈 삽입물
CA3177005A1 (en) 2020-04-27 2021-11-04 Michael Goldstein Methods of treating allergic conjunctivitis
KR102467288B1 (ko) * 2020-06-09 2022-11-17 동국대학교 산학협력단 결막 접촉용 약물 전달기
EP3928805A1 (en) * 2020-06-26 2021-12-29 Royal College of Surgeons in Ireland A device for use in the delivery of an active agent
CA3199736A1 (en) * 2020-11-23 2022-05-27 Sight Sciences, Inc. Formulations and methods for treating conditions of the eye
EP4346790A4 (en) * 2021-05-26 2025-04-16 The Texas A&M University System Biodegradable mucoadhesive pharmaceutical formulations and methods thereof
CN114869862A (zh) * 2022-04-24 2022-08-09 温州医科大学附属眼视光医院 一种带引流功能的青光眼手术缓释抗瘢痕膜及制备方法
WO2025050106A1 (en) * 2023-08-31 2025-03-06 University Of Tennessee Research Foundation Sustained release ocular implants

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090155326A1 (en) * 2007-11-12 2009-06-18 Mack Brendan C Layered drug delivery polymer monofilament fibers

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026559A (en) * 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US5177168A (en) * 1989-10-17 1993-01-05 Polymer Technology Corp. Polymeric compositions useful in oxygen permeable contact lenses
WO1996011671A1 (en) * 1994-10-12 1996-04-25 Focal, Inc. Targeted delivery via biodegradable polymers
US8273366B2 (en) 2002-06-05 2012-09-25 University Of Florida Research Foundation, Incorporated Ophthalmic drug delivery system
CA2601864A1 (en) * 2005-04-08 2006-10-19 Surmodics, Inc. Sustained release implants and methods for subretinal delivery of bioactive agents to treat or prevent retinal disease
CA2843097C (en) 2005-05-24 2015-10-27 Inspire M.D Ltd. Stent apparatuses for treatment via body lumens and methods of use
US8187245B2 (en) * 2006-09-28 2012-05-29 Sca Hygiene Products Ab Absorbent article, belt structure, manufacturing method for a belt structure and manufacturing method for an absorbent article
US8444970B2 (en) * 2006-10-27 2013-05-21 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
JP5323720B2 (ja) * 2006-12-18 2013-10-23 アルコン リサーチ， リミテッド 眼用薬物送達のためのデバイスおよび方法
US8361492B2 (en) * 2008-04-29 2013-01-29 Ocugenics, LLC Drug delivery system and methods of use
US8083347B2 (en) * 2008-04-29 2011-12-27 Ocugenics, LLC Drug delivery system and methods of use
US20100104654A1 (en) * 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
US20100291182A1 (en) * 2009-01-21 2010-11-18 Arsenal Medical, Inc. Drug-Loaded Fibers
EP2396070B1 (en) 2009-02-12 2024-12-04 Incept Llc Drug delivery through hydrogel plugs
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
CA2764862C (en) * 2009-06-25 2017-08-29 Optonol Ltd. Fiber matrix for maintaining space in soft tissues
KR102337046B1 (ko) 2010-01-22 2021-12-08 알러간, 인코포레이티드 전방내 서방성 치료제 이식물
US20110229551A1 (en) * 2010-03-17 2011-09-22 Notus Laboratories, Inc. Drug delivery compositions and methods using nanofiber webs
US9028860B2 (en) * 2010-04-28 2015-05-12 Poly-Med, Inc. Partially microcellular, selectively hydrophilic composite construct for ocular drug delivery
WO2012114138A1 (fr) * 2011-02-21 2012-08-30 Cerebel-Invest Sa Implants biodégradables pour la libération contrôlée sous-conjonctivale d'une molécule active
WO2012149278A1 (en) 2011-04-29 2012-11-01 Allergan, Inc. Sustained release latanoprost implant
ES2912370T3 (es) 2011-09-14 2022-05-25 Forsight Vision5 Inc Aparato para inserción ocular
CN203089455U (zh) * 2013-02-01 2013-07-31 浙江大学医学院附属第二医院 襻上镶嵌有药物缓释微囊的人工晶状体
ES2900025T3 (es) * 2014-09-06 2022-03-15 Integral Biosystems Llc Procedimientos y composiciones biocompatibles para lograr la liberación mantenida de fármaco en el ojo

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090155326A1 (en) * 2007-11-12 2009-06-18 Mack Brendan C Layered drug delivery polymer monofilament fibers

Also Published As

Publication number Publication date
AU2019250153B2 (en) 2021-02-04
CA2960213A1 (en) 2016-03-10
EP3188688A1 (en) 2017-07-12
AU2015311637A1 (en) 2017-03-23
US9931306B2 (en) 2018-04-03
EP3188688A4 (en) 2018-07-25
NZ729467A (en) 2024-04-26
US10328033B2 (en) 2019-06-25
ES2900025T3 (es) 2022-03-15
KR102456032B1 (ko) 2022-10-18
CA2960213C (en) 2023-03-28
EP3188688B1 (en) 2021-11-03
MY178327A (en) 2020-10-08
CN106604695B (zh) 2018-10-23
AU2019250153A1 (en) 2019-10-31
CN106604695A (zh) 2017-04-26
JP2022001582A (ja) 2022-01-06
CN109481447A (zh) 2019-03-19
ZA201701467B (en) 2018-04-25
KR20170052582A (ko) 2017-05-12
JP2017526655A (ja) 2017-09-14
JP7026507B2 (ja) 2022-02-28
SG11201701714RA (en) 2017-04-27
US20180280313A1 (en) 2018-10-04
US20170296483A1 (en) 2017-10-19
WO2016037169A1 (en) 2016-03-10
ZA201705792B (en) 2018-12-19

Similar Documents

Publication Publication Date Title
AU2019250153B2 (en) Methods and biocompatible compositions to achieve sustained drug release in the eye
CN111743878B (zh) 用于眼科应用和/或其它应用的组合物以及方法
JP2021038251A (ja) 改善された粘膜輸送を示す医薬用ナノ粒子
WO2008157614A2 (en) Sustained intraocular delivery of drugs from biodegradable polymeric microparticles
HK40003833A (en) Methods and biocompatible compositions to achieve sustained drug release in the eye
HK1235660B (en) Methods and biocompatible compositions to achieve sustained drug release in the eye
Tawfik Dual Drug-Loaded Electrospun Nanofibres for the Treatment of Corneal Diseases
Lavik et al. Sustained intraocular delivery of drugs from biodegradable polymeric microparticles
HK40039406B (en) Compositions and methods for ophthalmic and/or other applications
HK40039406A (en) Compositions and methods for ophthalmic and/or other applications
JP2015074641A (ja) 眼内薬物送達デバイスおよび付随する方法
HK40038233A (en) Pharmaceutical nanoparticles showing improved mucosal transport
HK40039407A (en) Compositions and methods for ophthalmic and/or other applications
HK40038231A (en) Pharmaceutical nanoparticles showing improved mucosal transport
HK40038232A (en) Pharmaceutical nanoparticles showing improved mucosal transport
AU2019204106A1 (en) Intraocular drug delivery device and associated methods
HK1226949A1 (en) Compositions and methods for ophthalmic and/or other applications
HK1226949B (zh) 用於眼科应用和/或其它应用的组合物以及方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)